Sponsored By

Vote

 


 

Vote Cybrexa

for Venture


Cybrexa

 

Name

Per Hellsund

 

Title

CEO

 

Company/Organization

Cybrexa, Inc

 

City/Town where Organization Located

New Haven, CT

 

Company/organization description (<500 characters)

Cybrexa is a privately-held biotechnology company dedicated to developing next-generation tumor-targeted cancer therapies using its alphalex™ platform. The Company’s lead candidate, CBX-12, an alphalex™-exatecan conjugate, is expected to enter Phase I in 2021 in advanced solid tumors. Cybrexa also has other preclinical toxin conjugate programs as well as synthetic lethality programs. Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies.

 

Tell us about the milestones your venture accomplished in 2019, eg., key team members added, revenue level achieved, major sales made or endorsements received, successful exit, etc... (<500 characters)

In 2019, we expanded our pipeline to four programs and selected a lead candidate, CBX-12, with high potential in solid tumors. Also, we expanded our chemistry and biology labs at 5 Science Park in New Haven and hired additional PhD scientists to progress our programs. Finally, we closed a $13.4M round of financing, bringing the total funds Cybrexa has raised to $31M.

 

Stage: Does your venture generate revenue? YES or NO

No

 

What CT entrepreneur ecosystem resources (spaces, programs, events, schools, etc.) have helped you succeed? (<500 characters)

Organizations like Connecticut Innovations, CTNext, and BioCT have been critical in providing financing and a network to grow our company in New Haven. Yale University and the Office of Cooperative Research have been instrumental in providing technology and expertise to advance our programs. Also, the amazing scientific talent in Connecticut has enabled our success - and to grow from a startup to a biotech on the cusp of entering the clinic with our first antitumor therapy in just three years

 

What people are saying about Cybrexa...

 Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of cancer therapies using its alphalex™ platform to deliver anti-cancer agents directly into tumor cells. The Company’s lead candidate, CBX-11, an alphalex™-PARP inhibitor combination, is in preclinical development with advancing plans to initiate clinical development. Cybrexa was founded by physician-scientists, and has an experienced management team that has built numerous successful life sciences companies and raised hundreds of millions of dollars in venture capital. For more information about Cybrexa, please visit www.cybrexa.com.  

Bill Kenney

 

 


 


 

Others in this category

 

Atelier Cho Thompson

 

Aureus Tech Inc

 

Bare Life

 

Byrd's Books

 

Conscious Capital Wealth Management

 

Convexity Scientific

 

DICOM Director

 

Encapsulate

 

Engagement Solutions

 

Enviro Power

 

Everything Bags inc

 

FinTron Invest

 

Framework Television

 

Geyser Remediation

 

Goat Boy Soaps

 

Green Check Verified

 

Green Home Solutions

 

Healthy PlanEat

 

Higher Education Literacy Professionals

 

Ivorleaf

 

Jubian

 

Karching

 

Lactation Innovations

 

Land Maverick

 

Levo International

 

Litchfield Distillery

 

Lolleez

 

Nami Therapeutics

 

New London Main Street

 

Noteworthy Chocolates

 

Oma's Pride

 

Paul's Custom Pet Food LLC

 

Phoenix Tailings

 

QRfertile

 

Rafael Goldstein and Tyler Lederer-Plaskett

 

Raise Green

 

ReNetX Bio

 

Ricker Duval

 

Roast Me

 

Rope Safe

 

SaniBrands, Inc.

 

Savkar

 

Silver Fern Healthcare

 

SnapSeat

 

Sound Affects

 

Sourcery

 

SphereGen

 

Stemify.AI

 

The Feel Good Lab

 

The Scoop Glastonbury

 

Therapeutic Bandage Products

 

Traveling Chic Boutique

 

Valisure

 

Villarina's Pasta Shop

 

 

Escort Girl